More Articles

Biosimilars as effective and safe as expensive biologicals Biosimilars/News | Posted 29/07/2009

Just like generic medicines, biosimilars could substantially reduce healthcare costs. Yet it seems that among physicians, pharmacists and patients there exists resistance against these cheaper vers...

International comparison of generic medicine prices Generics/Research | Posted 29/07/2009

The introduction of generic price-regulated systems in many European countries, the trend towards international generic medicine companies, and competition from Indian companies emphasises the need...

European generic prescribing trends and biosimilars Generics/Research | Posted 29/07/2009

Pressure to control pharmaceutical expenditure and price competition among pharmaceutical companies is fuelling the development of generic medicines markets in ambulatory care in Europe.

Growing western generic APIs markets in India and China Generics/General | Posted 29/07/2009

The developing countries India and China represent growing markets for active pharmaceutical ingredients (APIs) from western regulated markets. This is the conclusion of Ms Kate Kuhrt, Director of...

API opportunities in biologicals, biosimilars and generics Pharma News | Posted 29/07/2009

The active pharmaceutical ingredient (API) market, traditionally dominated by small-molecule drugs, is currently witnessing a rapid shift towards biopharmaceuticals. At the same time, the manufactu...

Branded cardiovascular drugs not better than generics Generics/Research | Posted 29/07/2009

In December 2008, the Journal of the American Medical Association published an article on the clinical equivalence of generic and brand-name drugs used in cardiovascular disease by Aaron Kesselheim...

Views on biosimilars: Genentech Biosimilars/News | Posted 29/07/2009

Genentech has put a clear position on biosimilars on its website. The company explains that the terms ‘biosimilar’ or ‘follow-on biologic’ refer to products that are marketed after expiration of pa...

European biosimilars market set to grow gradually Reports | Posted 29/07/2009

A new report from Frost & Sullivan (F&S) has claimed that despite the initial regulatory hiccups, the number of biosimilars in the European market is set to increase gradually. It notes tha...